Biotech Unusual Volume: Advaxis, Inc. (NASDAQ:ADXS), Endocyte (NASDAQ:ECYT), Clovis Oncology (NASDAQ:CLVS), Enzymotec Ltd (NASDAQ:ENZY)

Princeton-based Advaxis Inc. (NASDAQ:ADXS) announced Wednesday the pricing of a public offering of 4.08 million shares of common stock at $3.00 per share. Advaxis, Inc. (NASDAQ:ADXS) shares after opening at $3.04 moved to $3.08 on last trade day and at the end of the day closed at $3.06. Company price to sales ratio in past twelve months was calculated as – and price to cash ratio as 2.65. Advaxis, Inc. (NASDAQ:ADXS) showed a negative weekly performance of -37.93%.

Endocyte, Inc. (NASDAQ:ECYT) announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $21.00 per share. Endocyte, Inc. (NASDAQ:ECYT) shares fell -8.33% in last trading session and ended the day on $23.07. ECYT return on equity ratio is recorded as -19.70% and its return on assets is -9.90%. Endocyte, Inc. (NASDAQ:ECYT) yearly performance is 93.05%.

Clovis Oncology Inc. (NASDAQ:CLVS) Shares experienced a roller coaster after it posted positive findings from a study of its lung-cancer treatment. Clovis Oncology Inc. (NASDAQ:CLVS) shares moved up 3.64% in last trading session and was closed at $80.32, while trading in range of $72.50 – $80.88. Clovis Oncology Inc. (NASDAQ:CLVS) year to date (YTD) performance is 33.27%.

Enzymotec Ltd (NASDAQ:ENZY) share price has entered into oversold territory with an RSI value of 28.9. The Zacks Consensus Estimate for Enzymotec for the full year period has improved 7 cents over the past two months to 85 cents per share. Enzymotec Ltd (NASDAQ:ENZY) weekly performance is -19.73%. On last trading day company shares ended up $21.52. Enzymotec Ltd (NASDAQ:ENZY) distance from 50-day simple moving average (SMA50) is -19.16%. Analysts mean target price for the company is $29.00.